Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at upcoming conferences, including the American Society of Gene and Cell Therapy (ASGCT) and the Association for Research in Vision and Ophthalmology (ARVO). “We are pleased to be sharing these new preclinical non-human primate data that add to the growing body of evidence demonstrating ADVM-022 gene therapy’s long-term durability and safety,” said Mehdi Gasmi, Ph.D., president and chief scientific officer of Adverum Biotechnologies. “In an oral presentation at ASGCT, we will be presenting preclinical data to support that a single injection of 2x10^12 vg of ADVM-022 provides durable expression of aflibercept with no deleterious effects on retina structure and function observed out to 30 months. At ARVO, our poster presentation will
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingGlobeNewswire
- Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]Yahoo! Finance
ADVM
Earnings
- 11/9/23 - Miss
ADVM
Sec Filings
- 4/1/24 - Form EFFECT
- 3/27/24 - Form EFFECT
- 3/21/24 - Form S-3
- ADVM's page on the SEC website